"Thus, progression is present in most, if not all, patients with multiple sclerosis, regardless of where they are ...

Tysabri has been shown to be effective for treating multiple sclerosis (MS ... talk with your doctor before receiving Tysabri: Ocrevus is also approved to treat primary progressive MS, while ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $3.77. While earnings declined 6% year over year on a reported basis, it ...

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis ...

She was diagnosed with secondary progressive multiple sclerosis in 2010 ... As the availability of Ocrevus Zunuvo continues to increase across the country, Josh Weber, UVA Health’s director ...

Ocrevus (ocrelizumab ... cases of late onset (also called later-onset) multiple sclerosis have been documented in people in ...